Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.